CRISPR Therapeutics AG (CRSP) Research & Development (2015 - 2026)

CRISPR Therapeutics AG has reported Research & Development for 12 years, with the latest figure at $68.6 million in Q1 2026.

• Quarterly Research & Development fell 5.39% year-over-year to $68.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $210.4 million (down 31.37% YoY) and the FY2025 annual result came in at $284.8 million, down 8.2% from the prior year.
• Research & Development grew to $68.6 million in Q1 2026 per CRSP's latest filing, from $13.0 million in the prior quarter.
• Over five years, Research & Development peaked at $123.2 million in Q2 2022 and troughed at $13.0 million in Q4 2025.
• A 5-year average of $84.8 million and a median of $82.2 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 67.44% in 2022, then plunged 81.88% in 2025.
• Over 5 years, Research & Development stood at $103.6 million in 2022, then dropped by 8.12% to $95.1 million in 2023, then decreased by 24.6% to $71.7 million in 2024, then slumped by 81.88% to $13.0 million in 2025, then jumped by 427.49% to $68.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $68.6 million, $13.0 million, and $58.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.